Totally Endoscopic Ablation of Atrial Fibrillation

Region Örebro County36 enrolled

Overview

Primary Objective To evaluate the efficiency of totally endoscopic ablation of AF compared to rate control management of AF. Secondary Objectives Does totally endoscopic ablation: * reduce atrial fibrillation symptoms? * increase working capacity and improve quality of life? * improve atrial function? * reduce the risk for stroke?

This is a randomized open controlled single centre study that involves 60 patients (men and women) over the age of 50 years with longstanding persistent AF of more than one year duration and in the absence of other severe cardiopulmonary disease. One of the participating investigators informs the patient, both verbally and in writing, about the study and what participation in the study involves. The patient will be given time to ask questions and to consider study participation and can be enrolled in the study after signing and dating written Informed Consent. Study duration per patient is 12 months. After inclusion, the patient will be divided into one of two groups, treatment group or control group, according to block wise randomization. The patient will be asked to complete two health related questionnaires SF 36 and SCL and a transthoracic echocardiography will be conducted together with an exercise test. The patients will thereafter be assessed according to randomisation. Irrespective of group, the patients will be rescheduled for a visit within two months for totally endoscopic ablation and Reveal implantation or just Reveal implantation (control group). All patients will then be assessed during follow-ups after 1, 3, 6 and 12 months.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Atrial Fibrillation

Interventions

Endoscopic ablation of AFPROCEDURE

The procedure is conducted in general anaesthesia. The right chest is entered with three working ports . After a complete cycle of ablation creating a box lesion in the left atrium, conduction block is tested. A chest tube is placed through the most caudal port and the port incisions are closed. A Reveal loop recorder is then implanted subcutaneously. The patient is extubated and transferred to postoperative care.

Rate controlDRUG

Anti-arrhythmic protocol The control group is using a rate-control strategy. All patients keep their anti-arrhythmic/beta-blocker/digoxin medication during the entire follow-up. No attempts are made to rhythm-control the patients, unless subjective symptoms make it necessary.

Eligibility

Sex: ALLMin age: 50 YearsMax age: 85 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Age \> 50 years 2. Longstanding persistent AF of \> 1 year duration 3. Severe symptoms related to AF 4. Have signed and dated Informed Consent. 5. Willing and able to comply with the protocol for the duration of the trial. Exclusion Criteria: 1. Severe ischemic heart disease or heart valve disease 2. Thrombus formation in left atrial appendage 3. Intolerance to warfarin medication 4. Advanced pulmonary disease, FEV 1 \< 1.5 litre 5. Left atrial diameter \> 60 mm 6. Body Mass Index (BMI) \> 35 kg/m2 7. Previous pulmonary or heart surgery 8. Participation in another clinical trial within the last 30 days prior to enrollment

Locations (1)

Örebro University Hospital

Örebro, Sweden

Outcomes

Primary Outcomes

Freedom of AF 3 - 12 months postoperatively without antiarrhythmic drugs

Time frame: 3-12 months

Secondary Outcomes

Freedom of symptomatic AF episodes 3 - 12 months

Time frame: 3-12 months

Exercise capacity after 12 months

Time frame: 12 months

Quality-of-life assessment (SF-36 and SCL) 3, 6 and 12 months

Time frame: 12 months

Atrial function and dimensions after 6 and 12 months

Time frame: 12 months

Freedom of thromboembolic events during the study

Time frame: 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.